Aurinia gets two new assets in acquisition, licensing deal; Shorla preps T-cell leukemia drug for commercialization
Aurinia has acquired two new pipeline assets through a buyout and research collaboration, the Canadian biotech announced Tuesday.
The first new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
